64 related articles for article (PubMed ID: 20198607)
1. p53 flow cytometry evaluation in leukemias: correlation to factors affecting clinical outcome.
Cavalcanti GB; Scheiner MA; Simões Magluta EP; Vasconcelos FC; Klumb CE; Maia RC
Cytometry B Clin Cytom; 2010 Jul; 78(4):253-9. PubMed ID: 20198607
[TBL] [Abstract][Full Text] [Related]
2. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.
Cavalcanti GB; Vasconcelos FC; Pinto de Faria G; Scheiner MA; de Almeida Dobbin J; Klumb CE; Maia RC
Cytometry B Clin Cytom; 2004 Sep; 61(1):1-8. PubMed ID: 15351976
[TBL] [Abstract][Full Text] [Related]
3. P53 protein expression in human leukemia and lymphoma cells.
Koníková E; Kusenda J
Neoplasma; 2001; 48(4):290-8. PubMed ID: 11712681
[TBL] [Abstract][Full Text] [Related]
4. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometry of p53 protein expression in some hematological malignancies.
Koníková E; Kusenda J; Babusíková O
Neoplasma; 1999; 46(6):368-76. PubMed ID: 10732866
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukemia: correlation between purine metabolism enzyme activities and membrane immunophenotype.
Mesárosová A; Hrivnáková A; Klobusická M; Babusíková O
Neoplasma; 1995; 42(1):9-14. PubMed ID: 7617076
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
[TBL] [Abstract][Full Text] [Related]
9. p53 protein expression in leukemias.
Paydas S
Acta Oncol; 1995; 34(1):23-6. PubMed ID: 7865230
[TBL] [Abstract][Full Text] [Related]
10. P53, p15INK4B, p16INK4A and p57KIP2 mutations during the progression of chronic myeloid leukemia.
Güran S; Bahçe M; Beyan C; Korkmaz K; Yalçin A
Haematologia (Budap); 1998; 29(3):181-93. PubMed ID: 10069444
[TBL] [Abstract][Full Text] [Related]
11. The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoiesis.
Bi S; Lanza F; Goldman JM
Cancer Res; 1994 Jan; 54(2):582-6. PubMed ID: 8275497
[TBL] [Abstract][Full Text] [Related]
12. High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast.
Pavlova S; Mayer J; Koukalova H; Smardova J
Int J Oncol; 2003 Jul; 23(1):121-31. PubMed ID: 12792784
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease.
Krauth MT; Simonitsch I; Aichberger KJ; Mayerhofer M; Sperr WR; Sillaber C; Schneeweiss B; Mann G; Gadner H; Valent P
Am J Clin Pathol; 2004 Apr; 121(4):473-81. PubMed ID: 15080298
[TBL] [Abstract][Full Text] [Related]
14. Significance of FHIT expression in chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; O'Brien S; Manshouri T; Cortes J; Giles F; Rios MB; Croce CM; Albitar M
Clin Cancer Res; 1999 Dec; 5(12):4059-64. PubMed ID: 10632340
[TBL] [Abstract][Full Text] [Related]
15. Expression of programmed cell death proteins in patients with chronic myeloid leukemia.
Strnad M; Brajuskovic G; Strelic N; Todoric-Zivanovic B; Stamatovic D; Tatomirovic Z; Magic Z
J BUON; 2008; 13(3):403-8. PubMed ID: 18979557
[TBL] [Abstract][Full Text] [Related]
16. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of BCL-2 oncoprotein and Fas antigen on normal peripheral blood and leukemic bone marrow cells. A flow cytometric analysis.
Molica S; Mannella A; Dattilo A; Levato D; Iuliano F; Peta A; Consarino C; Magro S
Haematologica; 1996; 81(4):302-9. PubMed ID: 8870373
[TBL] [Abstract][Full Text] [Related]
18. Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies.
Orazi A; Cattoretti G; Heerema NA; Sozzi G; John K; Neiman RS
Mod Pathol; 1993 Sep; 6(5):521-5. PubMed ID: 8248107
[TBL] [Abstract][Full Text] [Related]
19. Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells.
Lawrence HJ; Sauvageau G; Ahmadi N; Lopez AR; LeBeau MM; Link M; Humphries K; Largman C
Exp Hematol; 1995 Oct; 23(11):1160-6. PubMed ID: 7556525
[TBL] [Abstract][Full Text] [Related]
20. Antibody-producing human-human hybridomas. III. Derivation and characterization of two antibodies with specificity for human myeloid cells.
Andreasen RB; Olsson L
J Immunol; 1986 Aug; 137(3):1083-90. PubMed ID: 3459756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
